China Chemical Pharmaceutical Industry Report, 2011
In Jan.-Aug., 2011, the gross industrial output value of Chinese chemical pharmaceutical industry surged by 24.54% YoY to RMB460.531 billion, up 2.67 percentage points over the same period of last year, presenting remarkable upward momentum. The chemical pharmaceutical industry of China chiefly comprises two sub-sectors chemical API and drug preparation which show differentiated development.
China is currently the world’s largest producer and exporter of chemical API and can produce more than 1,500 varieties with the capacity approximating 2 or 3 million tons. However, key bulk API products including vitamins and antibiotics witness overcapacity, which has resulted in low-price competition bringing adverse impact on the export of API. In Q1 2011, the API export of China increased by 39.53% year-on-year, with the export value rising 31.31% from the same period of last year, while the average export price fell 5.89% year-on-year. In particular, the average export price of Vitamin C slumped by 30%.
In comparison with chemical API sector, the chemical drug preparation sector of China enjoys higher profitability as a whole, with the gross margin in 2010 hitting 39.6% and two-fold of that of API industry. Yet, chemical preparation industry of China is still in its infancy with short R&D capability of new drugs, and therefore the production of generics is the mainstream.
The report focuses on the market size and development trend of China chemical pharmaceutical industry as well as the market scale of API and chemical preparation on the basis of the outlook for new drug R&D and market development worldwide. In addition, the market planning and new drug R&D of the leading 20 listed industrial players is also analyzed here.
Northeast Pharmaceutical Group Co., Ltd. is one of the largest Vitamin C producers in China. In 2011, the Vitamin C capacity of the company reached 25,000 tons. Currently, its investment is mainly earmarked for API. Also in 2011, it raised funds RMB2.645 billion to build Xihe-based API production base covering Vitamin C API, fosfomycin series products, L-carnitine series, and so forth.
As one of key chemical pharmaceutical companies in China, the operating revenue of. Huadong Medicine Co., Ltd in Jan.-Sep., 2011 increased by 25.51% year-on-year to RMB8.195 billion. Its holding subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, is regarded as the largest immunosuppressant producer in China.
Jiangsu Hengrui Medicine Co., Ltd is the one with the most new drugs independently developed among pharmaceutical companies in China. In 2011, it filed for the production of four new drugs with Class - and for the clinical trial of four new chemical medicines with class - and one biological medicine with class. Moreover, eleven new chemical medicines with class - and one biological medicine with class were under clinical trial. In December 2011, Irinotecan injection developed by Jiangsu Hengrui Medicine Co. won the FDA certification and became qualified to be sold in the US market, which made it be the first of this kind among Chinese peers.
China is currently the world’s largest producer and exporter of chemical API and can produce more than 1,500 varieties with the capacity approximating 2 or 3 million tons. However, key bulk API products including vitamins and antibiotics witness overcapacity, which has resulted in low-price competition bringing adverse impact on the export of API. In Q1 2011, the API export of China increased by 39.53% year-on-year, with the export value rising 31.31% from the same period of last year, while the average export price fell 5.89% year-on-year. In particular, the average export price of Vitamin C slumped by 30%.
In comparison with chemical API sector, the chemical drug preparation sector of China enjoys higher profitability as a whole, with the gross margin in 2010 hitting 39.6% and two-fold of that of API industry. Yet, chemical preparation industry of China is still in its infancy with short R&D capability of new drugs, and therefore the production of generics is the mainstream.
The report focuses on the market size and development trend of China chemical pharmaceutical industry as well as the market scale of API and chemical preparation on the basis of the outlook for new drug R&D and market development worldwide. In addition, the market planning and new drug R&D of the leading 20 listed industrial players is also analyzed here.
Northeast Pharmaceutical Group Co., Ltd. is one of the largest Vitamin C producers in China. In 2011, the Vitamin C capacity of the company reached 25,000 tons. Currently, its investment is mainly earmarked for API. Also in 2011, it raised funds RMB2.645 billion to build Xihe-based API production base covering Vitamin C API, fosfomycin series products, L-carnitine series, and so forth.
As one of key chemical pharmaceutical companies in China, the operating revenue of. Huadong Medicine Co., Ltd in Jan.-Sep., 2011 increased by 25.51% year-on-year to RMB8.195 billion. Its holding subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, is regarded as the largest immunosuppressant producer in China.
Jiangsu Hengrui Medicine Co., Ltd is the one with the most new drugs independently developed among pharmaceutical companies in China. In 2011, it filed for the production of four new drugs with Class - and for the clinical trial of four new chemical medicines with class - and one biological medicine with class. Moreover, eleven new chemical medicines with class - and one biological medicine with class were under clinical trial. In December 2011, Irinotecan injection developed by Jiangsu Hengrui Medicine Co. won the FDA certification and became qualified to be sold in the US market, which made it be the first of this kind among Chinese peers.
1. OVERVIEW OF CHEMICAL PHARMACEUTICAL INDUSTRY
1.1 Definition and Classification
1.2 Industry Chain
2. DEVELOPMENT OF GLOBAL CHEMICAL PHARMACEUTICAL INDUSTRY
2.1 Market Size
2.2 Supply and Demand
2.2.1 Product Mix
2.2.2 Regional Structure
2.3 Major Countries and Regions
2.3.1 North America
2.3.2 Europe
2.3.3 Japan
2.4 Development Trend
3. DEVELOPMENT OF CHINA CHEMICAL PHARMACEUTICAL INDUSTRY
3.1 Status Quo
3.2 Profitability
3.2.1 Chemical API
3.2.2 Chemical Preparation
3.3 Import & Export
3.3.1 Chemical API
3.3.2 Chemical Preparations
3.4 Competition
3.5 Development Prospect
3.5.1 Vast Space for Rise in Health Expenditure Per Capita
3.5.2 Aging Society, the Fundamental Driving Force
3.6 Major Projects under Construction of Chemical Pharmaceutical Industry
4. MARKET SEGMENT OF CHEMICAL PHARMACEUTICAL IN CHINA
4.1 Vitamins
4.1.1 Development
4.1.2 Competition
4.1.3 Import & Export
4.2 Antibiotics
4.2.1 Development
4.2.2 Competition
4.2.3 Import & Export
4.3 Antipyretic-analgesic Drugs
4.3.1 Development
4.3.2 Competition
4.3.3 Import and Export
4.4 Hormoues
4.4.1 Development
4.4.2 Competition
4.4.3 Import and Export
4.5 Antitumor Drugs
4.5.1 Development
4.5.2 Competition
4.6 Cardiovascular Drugs
4.6.1 Development
4.6.2 Competition
5. API PRODUCERS IN CHINA
5.1 Northeast Pharmaceutical Group Co., Ltd.
5.1.1 Profile
5.1.2 Operation
5.1.3 Competitive Edge and Development Trend
5.2 North China Pharmaceutical
5.2.1 Profile
5.2.2 Operation
5.2.3 Product Planning
5.2.4 Operating Strategy
5.3 Zhejiang Medicine Co., Ltd.
5.3.1 Profile
5.3.2 Operation
5.3.3 Fund-raising Projects in 2011
5.3.4 Development Prospect and Advantages
5.4 Zhejiang HISUN Pharmaceuticals Co., Ltd.
5.4.1 Profile
5.4.2 Operation
5.4.3 Development Outlook and Advantages
5.5 Zhejiang NHU Co., Ltd
5.5.1 Profile
5.5.2 Operation
5.5.3 Project Construction
5.6 Shandong Xinhua Pharmaceutical Co., Ltd.
5.6.1 Profile
5.6.2 Operation
5.6.3 Development Prospect & Advantages
5.7 Shenzhen Hepalink Pharmaceutical Co., Ltd.
5.7.1 Profile
5.7.2 Operation
5.7.3 Development Prospects and Advantages
5.8 Zhejiang Xianju Pharmaceutical Co., Ltd.
5.8.1 Profile
5.8.2 Operation
5.8.3 Development Prospects and Advantages
5.9 Zhejiang Huahai Pharmaceuticals Co., Ltd.
5.9.1 Profile
5.9.2 Operation
5.9.3 Development Prospect & Advantages
5.10 Tianjin Tianyao Pharmaceuticals Co., Ltd.
5.10.1 Profile
5.10.2 Operation
5.10.3 Development Prospect & Advantages
6. CHEMICAL PREPARATION MANUFACTURERS IN CHINA
6.1 Beijing Double-crane Pharmaceutical Co., Ltd.
6.1.1 Profile
6.1.2 Operation
6.1.3 Investment Planning
6.2 Jiangsu Hengrui Medicine Co., Ltd
6.2.1 Profile
6.2.2 Operation
6.2.3 R&D and Manufacture of New Drugs
6.3 Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co., Ltd.
6.3.1 Profile
6.3.2 Operation
6.4 Guangzhou Baiyunshan Pharmaceutical
6.4.1 Profile
6.4.2 Operation
6.4.3 Prospect
6.5 Livzon Pharmaceutical Group
6.5.1 Profile
6.5.2 Operation
6.5.3 Capacity Expansion
6.6 Fosun Pharma
6.6.1 Profile
6.6.2 Operation
6.6.3 Fund-raising Projects
6.7 Huapont Pharma.
6.7.1 Profile
6.7.2 Operation
6.7.3 Business Development
6.8 Hainan Haiyao Co., Ltd
6.8.1 Profile
6.8.2 Operation
6.8.3 Development Outlook
6.9 Jiangsu Nhwa Pharmaceutical Co., Ltd.
6.9.1 Profile
6.9.2 Operation
6.10 Huadong Medicine Co., Ltd.
6.10.1 Profile
6.10.2 Operation
6.10.3 Development Outlook
1.1 Definition and Classification
1.2 Industry Chain
2. DEVELOPMENT OF GLOBAL CHEMICAL PHARMACEUTICAL INDUSTRY
2.1 Market Size
2.2 Supply and Demand
2.2.1 Product Mix
2.2.2 Regional Structure
2.3 Major Countries and Regions
2.3.1 North America
2.3.2 Europe
2.3.3 Japan
2.4 Development Trend
3. DEVELOPMENT OF CHINA CHEMICAL PHARMACEUTICAL INDUSTRY
3.1 Status Quo
3.2 Profitability
3.2.1 Chemical API
3.2.2 Chemical Preparation
3.3 Import & Export
3.3.1 Chemical API
3.3.2 Chemical Preparations
3.4 Competition
3.5 Development Prospect
3.5.1 Vast Space for Rise in Health Expenditure Per Capita
3.5.2 Aging Society, the Fundamental Driving Force
3.6 Major Projects under Construction of Chemical Pharmaceutical Industry
4. MARKET SEGMENT OF CHEMICAL PHARMACEUTICAL IN CHINA
4.1 Vitamins
4.1.1 Development
4.1.2 Competition
4.1.3 Import & Export
4.2 Antibiotics
4.2.1 Development
4.2.2 Competition
4.2.3 Import & Export
4.3 Antipyretic-analgesic Drugs
4.3.1 Development
4.3.2 Competition
4.3.3 Import and Export
4.4 Hormoues
4.4.1 Development
4.4.2 Competition
4.4.3 Import and Export
4.5 Antitumor Drugs
4.5.1 Development
4.5.2 Competition
4.6 Cardiovascular Drugs
4.6.1 Development
4.6.2 Competition
5. API PRODUCERS IN CHINA
5.1 Northeast Pharmaceutical Group Co., Ltd.
5.1.1 Profile
5.1.2 Operation
5.1.3 Competitive Edge and Development Trend
5.2 North China Pharmaceutical
5.2.1 Profile
5.2.2 Operation
5.2.3 Product Planning
5.2.4 Operating Strategy
5.3 Zhejiang Medicine Co., Ltd.
5.3.1 Profile
5.3.2 Operation
5.3.3 Fund-raising Projects in 2011
5.3.4 Development Prospect and Advantages
5.4 Zhejiang HISUN Pharmaceuticals Co., Ltd.
5.4.1 Profile
5.4.2 Operation
5.4.3 Development Outlook and Advantages
5.5 Zhejiang NHU Co., Ltd
5.5.1 Profile
5.5.2 Operation
5.5.3 Project Construction
5.6 Shandong Xinhua Pharmaceutical Co., Ltd.
5.6.1 Profile
5.6.2 Operation
5.6.3 Development Prospect & Advantages
5.7 Shenzhen Hepalink Pharmaceutical Co., Ltd.
5.7.1 Profile
5.7.2 Operation
5.7.3 Development Prospects and Advantages
5.8 Zhejiang Xianju Pharmaceutical Co., Ltd.
5.8.1 Profile
5.8.2 Operation
5.8.3 Development Prospects and Advantages
5.9 Zhejiang Huahai Pharmaceuticals Co., Ltd.
5.9.1 Profile
5.9.2 Operation
5.9.3 Development Prospect & Advantages
5.10 Tianjin Tianyao Pharmaceuticals Co., Ltd.
5.10.1 Profile
5.10.2 Operation
5.10.3 Development Prospect & Advantages
6. CHEMICAL PREPARATION MANUFACTURERS IN CHINA
6.1 Beijing Double-crane Pharmaceutical Co., Ltd.
6.1.1 Profile
6.1.2 Operation
6.1.3 Investment Planning
6.2 Jiangsu Hengrui Medicine Co., Ltd
6.2.1 Profile
6.2.2 Operation
6.2.3 R&D and Manufacture of New Drugs
6.3 Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co., Ltd.
6.3.1 Profile
6.3.2 Operation
6.4 Guangzhou Baiyunshan Pharmaceutical
6.4.1 Profile
6.4.2 Operation
6.4.3 Prospect
6.5 Livzon Pharmaceutical Group
6.5.1 Profile
6.5.2 Operation
6.5.3 Capacity Expansion
6.6 Fosun Pharma
6.6.1 Profile
6.6.2 Operation
6.6.3 Fund-raising Projects
6.7 Huapont Pharma.
6.7.1 Profile
6.7.2 Operation
6.7.3 Business Development
6.8 Hainan Haiyao Co., Ltd
6.8.1 Profile
6.8.2 Operation
6.8.3 Development Outlook
6.9 Jiangsu Nhwa Pharmaceutical Co., Ltd.
6.9.1 Profile
6.9.2 Operation
6.10 Huadong Medicine Co., Ltd.
6.10.1 Profile
6.10.2 Operation
6.10.3 Development Outlook
SELECTED CHARTS
China’s Chemical Pharmaceutical Industry Segments
Chemical Pharmaceutical Industry Value-added Chain
Global Medicine Sales and Growth Rate, 2002-2010
M&A Transaction Value in Global Pharmaceutical Industry, 2004-2010
Global Number of Newly-launched Drugs, 2000-2010
Global Top 20 Best-selling Drugs, 2009-2010
Proportional Change of Global Generic Drug Sales, 2003-2010
Global Medicine Sales Structure by Region, 2009
Global Generic Drug Sales Structure by Region, 2009
Health Expenditure Share of GDP in the US and Canada, 1970-2007
Medicine Sales and YoY Growth Rate in North America, 2007-2010
Medicine Sales and Growth Rate in the US, 2001-2010
Health Expenditure Share of GDP in Germany and UK, 1970-2007
Medicine Sales in Europe, 2007-2010
Health Expenditure Share of GDP in Japan, 1970-2007
Sales of Japanese Pharmaceutical Market, 2007-2010
AAGR of Global and Major Regional Pharmaceutical Markets, 2010-2014
Gross Industrial Output Value and Sales of China Chemical Pharmaceutical Industry, 2007-2011
Proportion of Chemical Pharmaceutical Industrial Output Value to GDP in China, 2005-2010
Output of APIs in China, 2006- 2011
Industrial Output Value of APIs and Preparations in China, 2007-2010
Operating Revenue and Total Profit of China Chemical APIs Industry, 2007- 2011
Gross Margin and Sales Profit Margin of China Chemical APIs Industry, 2006-2010
Operating Revenue and Total Profit of China Chemical Preparation Industry, 2007- 2011
Gross Margin and Sales Profit Margin of China Chemical Preparation Industry, 2006-2010
China’s Export of Medicine (By Value), 2010
Chemical APIs Export, 2010
Top 5 APIs Companies in China by Export, 2010
Monthly Export Volume and Value of Chemical Finished Dosage Form in Unmeasured Dose in China, 2011
Top 10 Destinations of Chemical Finished Dosage Form in Unmeasured Dose Exported from China, Jan.-Sep.2011
Monthly Export Volume and Value of Chemical Finished Dosage Form in Measured Dose in China, 2011
Top 10 Destinations of Chemical Finished Dosage Form in Measured Dose Exported from China, Jan.-Sep.2011
Monthly Import Volume and Value of Chemical Finished Dosage Form in Unmeasured Dose in China, 2011
Top 10 Countries of Chemical Finished Dosage Form in Unmeasured Dose Imported by China, Jan.-Sep.2011
Monthly Import Volume and Value of Chemical Finished Dosage Form in Measured Dose in China, 2011
Top 10 Countries of Chemical Finished Dosage Form in Measured Dose Imported by China, Jan.-Sep.2011
Market Segment Share of Hospital Drug Procurement in China, 2009 (by Treatment Use)
Health Expenditure and GDP % in China, 2000-2010
Health Expenditure Pattern and % Change in China, 2000-2009
Population Age 65 & Over and % of Total in China, 1982-2010
Major Projects in Planning or under Construction of China Chemical Pharmaceutical Industry, 2010-2011
Output of Vitamin C in China, 2006-2011
Output of Vitamin C Sodium in China, 2006-2011
Market Prices of Primary Vitamin API in China, 2011
Main Manufacturers and Capacities of Vitamin A in China, 2010
Main Manufacturers and Capacities of Vitamin E in China, 2010
Main Manufacturers and Capacities of Vitamin C Powder in China, 2010
Main Manufacturers and Capacities of Vitamin B1 in China, 2010
Main Manufacturers and Capacities of Vitamin B2 in China, 2010
Main Manufacturers and Capacities of Vitamin B5 (Calcium Pantothenate) in China, 2010
Main Manufacturers and Capacities of Vitamin K3 in China, 2010
Main Manufacturers and Capacities of Vitamin H (Biotin) in China, 2010
Output of Main Antibiotic Preparation Products in China, 2009
Manufacturers and Capacities of Main Antibiotic Bulk Pharmaceutical Chemicals in China, 2010
Main Manufacturers and Capacities of 7-ACA/7-ADC in China, 2010
Import Volume and Amount of Antibiotics in China, 2008-2011
Export Volume and Amount of Antibiotics in China, 2008-2011
Aspirin Output of China, 2006-2011
Panadol Output of China, 2006-2011
Analgin Output of China, 2006-2011
Brufen Output of China, 2006-2011
Phenacetin Output of China, 2006-2011
Antipyrine Output of China, 2006-2011
Isopropyl Antipyrine Output of China, 2006-2011
Aminopyrine Output of China, 2006-2011
Aspirin I/E Volume and Value of China, Jan.-Sept. 2011
Panadol I/E Volume and Value of China, Jan.-Sept. 2011
Analgin I/E Volume and Value of China, Jan.-Sept. 2011
Brufen I/E Volume and Value of China, Jan.-Sept. 2011
Caffeine I/E Volume and Value of China, Jan.-Sept. 2011
Outputs of Major Hormonal Products of China, 2008-2011
Prices of Major Hormonal Products of China, 2008-2011
Export Volume and Value of China’s Major Steroidal Hormonal Products, 2010
Global Antitumor Drug Market Scale, 2003-2011
Competition among China’s Major Antitumor Drug Manufacturers, 2010
Sales of Cardiovascular Drugs in Chinese Hospital Market, 2010
Composition of Cardiovascular Drugs Available in Chinese Sample Hospitals, 2010
Market Share of Western Cardiovascular Drugs in China, 2007-2009 (By Company)
Top 10 Cardiovascular Drugs at Chinese Sample Hospital by Purchase Value, 2010
Operating Revenue and Net Income of Northeast Pharmaceutical, 2008-2011
Revenue of Northeast Pharmaceutical by Region, 2008-2011
Fundraising and Investment Projects of Northeast Pharmaceutical, 2011
Operating Revenue and Net Income of North China Pharmaceutical, 2008-2011
Revenue of North China Pharmaceutical by Products, 2009-2011
Gross Margin of North China Pharmaceutical by Products, 2009-2011
Revenue of North China Pharmaceutical by Region, 2008-2011
New Products of North China Pharmaceutical, 2012
Key Fields of Product Development of North China Pharmaceutical, 2012
Operating Revenue and Net Income of Zhejiang Medicine, 2008-2011
Revenue of Zhejiang Medicine by Products, 2008-2010
Revenue of Zhejiang Medicine by Region, 2008-2011
Operating Revenue and Net Income of Zhejiang Hisun Pharmaceutical, 2008-2011
Operating Margin of Zhejiang Hisun Pharmaceutical, 2007-2011
Operating Revenue from Self-Made Drugs and Proportion of Zhejiang Hisun Pharmaceutical, 2008-2011
Operating Revenue Breakdown of Zhejiang Hisun Pharmaceutical by Product, 2008-2011
Operating Revenue of Zhejiang Hisun Pharmaceutical by Region, 2008-2011
Industry Upgrading Roadmap of Zhejiang Hisun Pharmaceutical, 2007-2013
Operating Revenue and Net Income of Zhejiang NHU Co., Ltd, 2008-2011
Revenue of Zhejiang NHU Co., Ltd by Product
Revenue of Zhejiang NHU by Region, 2009-2011
VE Production Line Off-Site Renovation Project of Zhejiang NHU Co., Ltd
Projects Concerning Flavors & Fragrances Business of Zhejiang NHU Co., Ltd
Operating Revenue and Net Income of Shandong Xinhua Pharmaceutical, 2008-2011
Gross Margin of Main Business of Shandong Xinhua Pharmaceutical by Product, 2009-2011
Revenue of Shandong Xinhua Pharmaceutical by Region, 2009-2011
Domestic Market Share of Main Products of Shandong Xinhua Pharmaceutical, 2010
Operating Revenue and Net Income of Hepalink, 2008-2011
Revenue of Hepalink by Product, 2009-2011
Gross Margin of Hepalink by Product, 2009-2011
Revenue of Hepalink by Region, 2009-2011
Export Volume, Value and Average Prices of Major Chinese Heparin Sodium Enterprises, Jan.-Sep.2009
Operating Revenue and Net Income of Xianju Pharmaceutical, 2008-2011
Revenue of Xianju Pharmaceutical by Product, 2009-2011
Gross Margin of Xianju Pharmaceutical by Product, 2009-2011
Revenue of Xianju Pharmaceutical by Region, 2009-2011
Newly Launched Projects of Xianju Pharmaceutical, 2011-2012
Operating Revenue and Net Income of Zhejiang Huahai Pharmaceuticals, 2008-2011
Revenue of Zhejiang Huahai Pharmaceuticals by Product, 2009-2011
Gross Margin of Zhejiang Huahai Pharmaceuticals, 2009-2011
Revenue of Zhejiang Huahai Pharmaceuticals by Region, 2009-2011
Investment Projects with Raised Funds of Zhejiang Huahai Pharmaceuticals, 2011
Operating Revenue and Net Income of Tianjin Tianyao Pharmaceuticals, 2008-2011
Revenue of Tianjin Tianyao Pharmaceuticals by Product, 2009-2011
Gross Margin of Tianjin Tianyao Pharmaceuticals by Product, 2009-2011
Revenue of Tianjin Tianyao Pharmaceuticals by Region, 2009-2011
API Output of Tianjin Tianyao Pharmaceuticals, 2007-2010
Market Shares of Some Products of Tianjin Tianyao Pharmaceuticals, 2010
Additional Issuance Projects of Tianjin Tianyao Pharmaceuticals, 2011
New Capacities of Additional Issuance Projects of Tianjin Tianyao Pharmaceuticals, 2011
Operating Revenue and Net Income of Beijing Double-crane Pharmaceutical, 2008-2011
Operating Revenue Breakdown of Beijing Double-crane Pharmaceutical by Product, 2008-2011
Operating Revenue Breakdown of Beijing Double-crane Pharmaceutical by Region, 2010
Investments of Beijing Double-crane Pharmaceutical for Projects under Construction, 2011
Operating Revenue and Net Income of Jiangsu Hengrui Medicine, 2008-2011
Operating Revenue Breakdown of Jiangsu Hengrui Medicine by Product, 2008-2011
Operating Revenue Breakdown of Jiangsu Hengrui Medicine by Region, 2010
New Drug R&D and Production of Jiangsu Hengrui Medicine, 2008-2010
Operating Revenue and Net Income of Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co., Ltd., 2008-2011
Operating Revenue Breakdown of Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co., Ltd by Product, 2008-2011
Operating Revenue Breakdown of Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co., Ltd by Region, 2010
Operating Revenue and Net Income of Guangzhou Baiyunshan Pharmaceutical Co., Ltd., 2008-2011
Operating Revenue Breakdown of Guangzhou Baiyunshan Pharmaceutical by Business, 2008-2011
Operating Revenue Breakdown of Guangzhou Baiyunshan Pharmaceutical by Region, 2010
Operating Revenue and Net Income of Livzon Group, 2008-2011
Operating Revenue Breakdown of Livzon Group (by Product)
Operating Revenue Breakdown of Livzon Group (by Region)
Investment Projects of Livzon Group, 2008-2011
Fosun’s Operating Revenue and Net Income, 2008-2011
Fosun’s Operating Revenue Structure, 2008-2011 (by Business)
Fosun’s Operating Revenue Structure, 2010 (by Region)
Fosun’s Fund-raising Projects, 2011
Huapont’s Operating Revenue and Net Income, 2008-2011
Huapont’s Operating Revenue Breakdown, H1 2011 (by Business)
Huapont’s Operating Revenue Breakdown, H1 2011 (by Region)
Operating Revenue and Net Income of Hainan Haiyao Co., Ltd, 2008-2011
Revenue of Hainan Haiyao Co., Ltd by Product, 2010-2011
Revenue of Hainan Haiyao Co., Ltd by Region, 2009-2011
Planned Construction Projects through Private Placement of Hainan Haiyao Co., Ltd, 2011
Operating Revenue and Net Income of Jiangsu Nhwa Pharmaceutical Co., Ltd., 2008-2011
Operating Revenue from API and Preparation (by Product) of Jiangsu Nhwa Pharmaceutical Co., Ltd., 2008-2011
Operating Revenue and Net Income of Huadong Medicine Co., Ltd., 2008-2011
Operating Revenue of Huadong Medicine Co., Ltd. (by Product), 2008-2011
Operating Revenue Breakdown of Huadong Medicine Co., Ltd. (by Region), 2010
China’s Chemical Pharmaceutical Industry Segments
Chemical Pharmaceutical Industry Value-added Chain
Global Medicine Sales and Growth Rate, 2002-2010
M&A Transaction Value in Global Pharmaceutical Industry, 2004-2010
Global Number of Newly-launched Drugs, 2000-2010
Global Top 20 Best-selling Drugs, 2009-2010
Proportional Change of Global Generic Drug Sales, 2003-2010
Global Medicine Sales Structure by Region, 2009
Global Generic Drug Sales Structure by Region, 2009
Health Expenditure Share of GDP in the US and Canada, 1970-2007
Medicine Sales and YoY Growth Rate in North America, 2007-2010
Medicine Sales and Growth Rate in the US, 2001-2010
Health Expenditure Share of GDP in Germany and UK, 1970-2007
Medicine Sales in Europe, 2007-2010
Health Expenditure Share of GDP in Japan, 1970-2007
Sales of Japanese Pharmaceutical Market, 2007-2010
AAGR of Global and Major Regional Pharmaceutical Markets, 2010-2014
Gross Industrial Output Value and Sales of China Chemical Pharmaceutical Industry, 2007-2011
Proportion of Chemical Pharmaceutical Industrial Output Value to GDP in China, 2005-2010
Output of APIs in China, 2006- 2011
Industrial Output Value of APIs and Preparations in China, 2007-2010
Operating Revenue and Total Profit of China Chemical APIs Industry, 2007- 2011
Gross Margin and Sales Profit Margin of China Chemical APIs Industry, 2006-2010
Operating Revenue and Total Profit of China Chemical Preparation Industry, 2007- 2011
Gross Margin and Sales Profit Margin of China Chemical Preparation Industry, 2006-2010
China’s Export of Medicine (By Value), 2010
Chemical APIs Export, 2010
Top 5 APIs Companies in China by Export, 2010
Monthly Export Volume and Value of Chemical Finished Dosage Form in Unmeasured Dose in China, 2011
Top 10 Destinations of Chemical Finished Dosage Form in Unmeasured Dose Exported from China, Jan.-Sep.2011
Monthly Export Volume and Value of Chemical Finished Dosage Form in Measured Dose in China, 2011
Top 10 Destinations of Chemical Finished Dosage Form in Measured Dose Exported from China, Jan.-Sep.2011
Monthly Import Volume and Value of Chemical Finished Dosage Form in Unmeasured Dose in China, 2011
Top 10 Countries of Chemical Finished Dosage Form in Unmeasured Dose Imported by China, Jan.-Sep.2011
Monthly Import Volume and Value of Chemical Finished Dosage Form in Measured Dose in China, 2011
Top 10 Countries of Chemical Finished Dosage Form in Measured Dose Imported by China, Jan.-Sep.2011
Market Segment Share of Hospital Drug Procurement in China, 2009 (by Treatment Use)
Health Expenditure and GDP % in China, 2000-2010
Health Expenditure Pattern and % Change in China, 2000-2009
Population Age 65 & Over and % of Total in China, 1982-2010
Major Projects in Planning or under Construction of China Chemical Pharmaceutical Industry, 2010-2011
Output of Vitamin C in China, 2006-2011
Output of Vitamin C Sodium in China, 2006-2011
Market Prices of Primary Vitamin API in China, 2011
Main Manufacturers and Capacities of Vitamin A in China, 2010
Main Manufacturers and Capacities of Vitamin E in China, 2010
Main Manufacturers and Capacities of Vitamin C Powder in China, 2010
Main Manufacturers and Capacities of Vitamin B1 in China, 2010
Main Manufacturers and Capacities of Vitamin B2 in China, 2010
Main Manufacturers and Capacities of Vitamin B5 (Calcium Pantothenate) in China, 2010
Main Manufacturers and Capacities of Vitamin K3 in China, 2010
Main Manufacturers and Capacities of Vitamin H (Biotin) in China, 2010
Output of Main Antibiotic Preparation Products in China, 2009
Manufacturers and Capacities of Main Antibiotic Bulk Pharmaceutical Chemicals in China, 2010
Main Manufacturers and Capacities of 7-ACA/7-ADC in China, 2010
Import Volume and Amount of Antibiotics in China, 2008-2011
Export Volume and Amount of Antibiotics in China, 2008-2011
Aspirin Output of China, 2006-2011
Panadol Output of China, 2006-2011
Analgin Output of China, 2006-2011
Brufen Output of China, 2006-2011
Phenacetin Output of China, 2006-2011
Antipyrine Output of China, 2006-2011
Isopropyl Antipyrine Output of China, 2006-2011
Aminopyrine Output of China, 2006-2011
Aspirin I/E Volume and Value of China, Jan.-Sept. 2011
Panadol I/E Volume and Value of China, Jan.-Sept. 2011
Analgin I/E Volume and Value of China, Jan.-Sept. 2011
Brufen I/E Volume and Value of China, Jan.-Sept. 2011
Caffeine I/E Volume and Value of China, Jan.-Sept. 2011
Outputs of Major Hormonal Products of China, 2008-2011
Prices of Major Hormonal Products of China, 2008-2011
Export Volume and Value of China’s Major Steroidal Hormonal Products, 2010
Global Antitumor Drug Market Scale, 2003-2011
Competition among China’s Major Antitumor Drug Manufacturers, 2010
Sales of Cardiovascular Drugs in Chinese Hospital Market, 2010
Composition of Cardiovascular Drugs Available in Chinese Sample Hospitals, 2010
Market Share of Western Cardiovascular Drugs in China, 2007-2009 (By Company)
Top 10 Cardiovascular Drugs at Chinese Sample Hospital by Purchase Value, 2010
Operating Revenue and Net Income of Northeast Pharmaceutical, 2008-2011
Revenue of Northeast Pharmaceutical by Region, 2008-2011
Fundraising and Investment Projects of Northeast Pharmaceutical, 2011
Operating Revenue and Net Income of North China Pharmaceutical, 2008-2011
Revenue of North China Pharmaceutical by Products, 2009-2011
Gross Margin of North China Pharmaceutical by Products, 2009-2011
Revenue of North China Pharmaceutical by Region, 2008-2011
New Products of North China Pharmaceutical, 2012
Key Fields of Product Development of North China Pharmaceutical, 2012
Operating Revenue and Net Income of Zhejiang Medicine, 2008-2011
Revenue of Zhejiang Medicine by Products, 2008-2010
Revenue of Zhejiang Medicine by Region, 2008-2011
Operating Revenue and Net Income of Zhejiang Hisun Pharmaceutical, 2008-2011
Operating Margin of Zhejiang Hisun Pharmaceutical, 2007-2011
Operating Revenue from Self-Made Drugs and Proportion of Zhejiang Hisun Pharmaceutical, 2008-2011
Operating Revenue Breakdown of Zhejiang Hisun Pharmaceutical by Product, 2008-2011
Operating Revenue of Zhejiang Hisun Pharmaceutical by Region, 2008-2011
Industry Upgrading Roadmap of Zhejiang Hisun Pharmaceutical, 2007-2013
Operating Revenue and Net Income of Zhejiang NHU Co., Ltd, 2008-2011
Revenue of Zhejiang NHU Co., Ltd by Product
Revenue of Zhejiang NHU by Region, 2009-2011
VE Production Line Off-Site Renovation Project of Zhejiang NHU Co., Ltd
Projects Concerning Flavors & Fragrances Business of Zhejiang NHU Co., Ltd
Operating Revenue and Net Income of Shandong Xinhua Pharmaceutical, 2008-2011
Gross Margin of Main Business of Shandong Xinhua Pharmaceutical by Product, 2009-2011
Revenue of Shandong Xinhua Pharmaceutical by Region, 2009-2011
Domestic Market Share of Main Products of Shandong Xinhua Pharmaceutical, 2010
Operating Revenue and Net Income of Hepalink, 2008-2011
Revenue of Hepalink by Product, 2009-2011
Gross Margin of Hepalink by Product, 2009-2011
Revenue of Hepalink by Region, 2009-2011
Export Volume, Value and Average Prices of Major Chinese Heparin Sodium Enterprises, Jan.-Sep.2009
Operating Revenue and Net Income of Xianju Pharmaceutical, 2008-2011
Revenue of Xianju Pharmaceutical by Product, 2009-2011
Gross Margin of Xianju Pharmaceutical by Product, 2009-2011
Revenue of Xianju Pharmaceutical by Region, 2009-2011
Newly Launched Projects of Xianju Pharmaceutical, 2011-2012
Operating Revenue and Net Income of Zhejiang Huahai Pharmaceuticals, 2008-2011
Revenue of Zhejiang Huahai Pharmaceuticals by Product, 2009-2011
Gross Margin of Zhejiang Huahai Pharmaceuticals, 2009-2011
Revenue of Zhejiang Huahai Pharmaceuticals by Region, 2009-2011
Investment Projects with Raised Funds of Zhejiang Huahai Pharmaceuticals, 2011
Operating Revenue and Net Income of Tianjin Tianyao Pharmaceuticals, 2008-2011
Revenue of Tianjin Tianyao Pharmaceuticals by Product, 2009-2011
Gross Margin of Tianjin Tianyao Pharmaceuticals by Product, 2009-2011
Revenue of Tianjin Tianyao Pharmaceuticals by Region, 2009-2011
API Output of Tianjin Tianyao Pharmaceuticals, 2007-2010
Market Shares of Some Products of Tianjin Tianyao Pharmaceuticals, 2010
Additional Issuance Projects of Tianjin Tianyao Pharmaceuticals, 2011
New Capacities of Additional Issuance Projects of Tianjin Tianyao Pharmaceuticals, 2011
Operating Revenue and Net Income of Beijing Double-crane Pharmaceutical, 2008-2011
Operating Revenue Breakdown of Beijing Double-crane Pharmaceutical by Product, 2008-2011
Operating Revenue Breakdown of Beijing Double-crane Pharmaceutical by Region, 2010
Investments of Beijing Double-crane Pharmaceutical for Projects under Construction, 2011
Operating Revenue and Net Income of Jiangsu Hengrui Medicine, 2008-2011
Operating Revenue Breakdown of Jiangsu Hengrui Medicine by Product, 2008-2011
Operating Revenue Breakdown of Jiangsu Hengrui Medicine by Region, 2010
New Drug R&D and Production of Jiangsu Hengrui Medicine, 2008-2010
Operating Revenue and Net Income of Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co., Ltd., 2008-2011
Operating Revenue Breakdown of Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co., Ltd by Product, 2008-2011
Operating Revenue Breakdown of Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co., Ltd by Region, 2010
Operating Revenue and Net Income of Guangzhou Baiyunshan Pharmaceutical Co., Ltd., 2008-2011
Operating Revenue Breakdown of Guangzhou Baiyunshan Pharmaceutical by Business, 2008-2011
Operating Revenue Breakdown of Guangzhou Baiyunshan Pharmaceutical by Region, 2010
Operating Revenue and Net Income of Livzon Group, 2008-2011
Operating Revenue Breakdown of Livzon Group (by Product)
Operating Revenue Breakdown of Livzon Group (by Region)
Investment Projects of Livzon Group, 2008-2011
Fosun’s Operating Revenue and Net Income, 2008-2011
Fosun’s Operating Revenue Structure, 2008-2011 (by Business)
Fosun’s Operating Revenue Structure, 2010 (by Region)
Fosun’s Fund-raising Projects, 2011
Huapont’s Operating Revenue and Net Income, 2008-2011
Huapont’s Operating Revenue Breakdown, H1 2011 (by Business)
Huapont’s Operating Revenue Breakdown, H1 2011 (by Region)
Operating Revenue and Net Income of Hainan Haiyao Co., Ltd, 2008-2011
Revenue of Hainan Haiyao Co., Ltd by Product, 2010-2011
Revenue of Hainan Haiyao Co., Ltd by Region, 2009-2011
Planned Construction Projects through Private Placement of Hainan Haiyao Co., Ltd, 2011
Operating Revenue and Net Income of Jiangsu Nhwa Pharmaceutical Co., Ltd., 2008-2011
Operating Revenue from API and Preparation (by Product) of Jiangsu Nhwa Pharmaceutical Co., Ltd., 2008-2011
Operating Revenue and Net Income of Huadong Medicine Co., Ltd., 2008-2011
Operating Revenue of Huadong Medicine Co., Ltd. (by Product), 2008-2011
Operating Revenue Breakdown of Huadong Medicine Co., Ltd. (by Region), 2010
